Publications by authors named "Leonardo Allegretta"
Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease.
Front Med (Lausanne)
February 2025
The role of gut microbiota (GM) in the pathogenesis of Symptomatic Uncomplicated Diverticular Disease (SUDD) remains controversial. Here, we assessed the efficacy of a butyrate formulation in modulating GM and abdominal pain in patients with SUDD. A retrospective study was conducted in patients with SUDD who were treated with a delayed- and colonic-release formulation of butyrate (two capsules bid, for a total dose of 400 mg butyrate) for 3 months.
View Article and Find Full Text PDFUstekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFGut microbiota in symptomatic uncomplicated diverticular disease stratifies by severity of abdominal pain.
Eur J Gastroenterol Hepatol
February 2025
Objective: Patients with symptomatic uncomplicated diverticular disease (SUDD) may have a disrupted gut microbiota. However, current data are from small sample studies, and reported associations vary widely across studies. We aimed to profile the fecal microbiota in SUDD patients enrolled in primary care.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at patients with diverticular disease (DD) and how their bowel movements, like constipation and diarrhea, relate to the seriousness of their condition.
- Researchers measured the severity using different tools and checked how changes in bowel habits might predict future health problems.
- They found that people with worse constipation or diarrhea had more severe DD and were more likely to develop a serious illness called acute diverticulitis over three years.
Background: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in patients with UC in a real-world setting.
Research Design And Methods: This is a multicenter, retrospective, observational cohort study.
Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis.
United European Gastroenterol J
September 2023
Background And Aims: The Diverticular Inflammation and Complication Assessment (DICA) classification and the Combined Overview on Diverticular Assessment (CODA) were found to be effective in predicting the outcomes of Diverticular Disease (DD). We ascertain whether fecal calprotectin (FC) can further aid in improving risk stratification.
Methods: A three-year international, multicentre, prospective cohort study was conducted involving 43 Gastroenterology and Endoscopy centres.
Background: Data regarding the real-world (RW) use of tofacitinib (TOF) in patients with ulcerative colitis (UC) are limited. We aimed to investigate TOF's RW efficacy and safety in Italian UC patients.
Research Design And Methods: A retrospective assessment of clinical and endoscopic activity was performed according to the Mayo score.
Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis.
Am J Gastroenterol
November 2023
Article Synopsis
- A study examined the occurrence and effects of segmental colitis linked to diverticulosis (SCAD) in patients with newly diagnosed diverticulosis over three years, involving 2,215 patients.
- Out of these patients, 44 were diagnosed with SCAD, resulting in a prevalence rate of 1.99%, with most patients being around 64.5 years old.
- While SCAD often has mild effects, types B and D of the condition were related to more severe symptoms and poorer outcomes, such as higher steroid use and lesser chances of complete recovery.
Background: Vedolizumab (VDZ) can be used to treat refractory ulcerative colitis (UC) and Crohn's disease (CD). We assessed whether there are differences in treating UC vs CD with VDZ.
Research Design And Methods: Mayo score in UC and the Harvey-Bradshaw Index (HBI) in CD scored the clinical activity.
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy.
J Gastrointestin Liver Dis
December 2022
Article Synopsis
- A study was conducted to compare the efficacy and safety of four adalimumab (ADA) biosimilars in patients with inflammatory bowel disease (IBD) after they were switched from the original ADA for non-medical reasons.
- Out of 153 IBD patients, 81% maintained clinical remission during a 12-month follow-up, and there was no significant difference in outcomes among the four biosimilars.
- However, patients with ulcerative colitis (UC) experienced a higher loss of remission compared to those with Crohn's disease (CD), indicating that switching biosimilars in UC patients may require careful evaluation.
Article Synopsis
- The approval of adalimumab biosimilars has led to lower treatment costs for inflammatory bowel disease (IBD).
- A study compared the effectiveness and safety of the biosimilar GP2017 (Hyrimoz) to the original drug Humira in IBD patients in Italy.
- Results showed similar rates of clinical remission and good tolerance for both treatments, indicating that GP2017 is as effective and safe as its original counterpart.
Article Synopsis
- Adalimumab (ADA) biosimilars are more affordable options for treating inflammatory bowel disease (IBD), but data comparing their effectiveness and safety remains limited.* -
- A study analyzed 533 IBD patients in Italy, measuring clinical activity, remission induction, and safety across four ADA biosimilars (SB5, ABP501, GP2017, and MSB11022).* -
- Results showed high clinical remission rates (79.6% for new biologics and 81.0% for patients switched from the ADA originator) with low adverse events (6.7%), indicating similar efficacy and safety among the different biosimilars.*
Background: To compare the performances of Infliximab (IFX) biosimilar CT-P13 and SB2 in the treatment of Inflammatory Bowel Diseases (IBD) outpatients in Italy.
Research Design And Methods: Three hundred and eighty IBD outpatients were retrospectively evaluated. The primary endpoint was to compare the two IFX biosimilars in terms of reaching and maintenance of remission at any timepoint.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
J Gastrointestin Liver Dis
December 2021
Background And Aims: Several studies have found Golimumab (GOL) effective and safe in the short-term treatment of ulcerative colitis (UC), but few long-term data are currently available from real world. Our aim was to assess the long-term real-life efficacy and safety of GOL in managing UC outpatients in Italy.
Methods: A retrospective multicenter study assessing consecutive UC outpatients treated with GOL for at least 3-month of follow-up was made.
Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study.
Gut
July 2022
Objective: To investigate the predictive value of the Diverticular Inflammation and Complication Assessment (DICA) classification and to develop and validate a combined endoscopic-clinical score predicting clinical outcomes of diverticulosis, named Combined Overview on Diverticular Assessment (CODA).
Design: A multicentre, prospective, international cohort study.
Setting: 43 gastroenterology and endoscopy centres located in Europe and South America.
Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care.
Rev Recent Clin Trials
October 2021
Background: Although FD may affect up to 10% of the general population, the therapy for FD is not standard. Recently, ginger-based food supplements have been proposed in order to restore FD symptoms. Our aim was to assess the efficacy of a new nutraceutical formulation containing extract of gingerol and thymus as a possible natural treatment in managing the symptoms of functional dyspepsia (FD).
View Article and Find Full Text PDFArticle Synopsis
- Infliximab and adalimumab are both commonly used medications for treating Crohn's disease and ulcerative colitis, and this study aimed to evaluate their long-term effectiveness and safety in real-life clinical settings.
- A total of 712 patients were reviewed, showing that both treatments maintained clinical remission similarly in Crohn's disease, but infliximab showed better results for ulcerative colitis.
- Adalimumab had a significantly lower rate of adverse events compared to infliximab, making it a potentially safer option for patients.
Background: The purpose of this study was to assess the efficacy and safety of biosimilar infliximab (IFX) CT-P13 in treating outpatients with inflammatory bowel disease (IBD) in Italian primary gastroenterology centers.
Methods: Consecutive IBD outpatients who completed the induction treatment were evaluated retrospectively. Clinical activity was scored according to the Mayo score for ulcerative colitis (UC) and to the Harvey-Bradshaw Index (HBI) for Crohn's disease (CD).
Background: Italian data currently available in managing ulcerative colitis (UC) and Crohn's disease (CD) patients with vedolizumab (VDZ) are coming just from secondary and tertiary centers. The present study aimed to assess the real-life efficacy and safety of VDZ to achieve remission in inflammatory bowel diseases (IBD) outpatients in primary gastroenterology centers.
Methods: Clinical activity was scored according to the Mayo score in UC and to the Harvey-Bradshaw Index (HBI) in CD.
Adalimumab (ADA) was approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments in 2014, but no data from real life are currently available. The aim of the present study was to assess the real-life efficacy and safety of ADA in managing UC outpatients in some Italian primary inflammatory bowel disease (IBD) centers after approval of ADA reimbursement.Consecutive UC outpatients with at least 3-month follow-up were retrospectively evaluated.
View Article and Find Full Text PDFBackground: Our aims were to assess the real life effectiveness and safety of the new bismuth-containing quadruple therapy in a large population of patients infected by Helicobacter pylori.
Methods: Consecutive dyspeptic H. pylori-positive patients were enrolled, both naïve for treatment and already unsuccessfully treated.
Background And Aims: Golimumab (GOL) has been recently approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments. Our aims were to assess the real-life efficacy and safety of GOL in managing UC outpatients in Italian primary Inflammatory Bowel Diseases (IBD) centres.
Methods: Consecutive UC outpatients with at least 3-months follow-up were enrolled.
Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
Minerva Gastroenterol Dietol
December 2017
Background: The aim of this study was to assess the efficacy and safety of infliximab biosimilar (IFX) IFX CT-P13 in inducing and maintaining remission in ulcerative colitis (UC) outpatients in Italian primary gastroenterology centers.
Methods: Patients were prospectively assessed at entry, after 8, 12, 24, 36, and therefore 52 weeks. Clinical activity was rated as per the Mayo Score.
Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis.
Clin Res Hepatol Gastroenterol
November 2016